Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic hcv infection: a meta-analysis
- Lampertico, Pietro
- Carrión, Jose A
- Curry, Michael
- Turnes, Juan
- Cornberg, Markus
- Negro, Francesco
- Brown, Ashley
- Persico, Marcello
- Wick, Nicole
- Porcalla, Ariel
- Pangerl, Andreas
- Crown, Eric
- Larsen, Lois
- Yu, Yao
- Wedemeyer, Heiner
DOIAbstract
Glecaprevir/pibrentasvir is approved for treating adults infected with HCV genotypes 1-6. In clinical trials, glecaprevir/pibrentasvir was associated with high rates of sustained virologic response at post-treatment week 12 (SVR12) and was well tolerated. A systematic review and meta-analysis of the real-world effectiveness and safety of glecaprevir/pibrentasvir were undertaken
Add to ORKG